UNITED THERAPEUTICS Corp: insider trades · United States · SEC (Form 4)

About UNITED THERAPEUTICS Corp

United Therapeutics Corp. (ticker: UTHR) is a U.S.-based biopharmaceutical company listed on the NASDAQ market in the United States, with its principal headquarters in Silver Spring, Maryland. Founded in 1996, the company has built a focused franchise around pulmonary vascular disease and select rare diseases, giving it a specialized market position with relatively defensive characteristics and a revenue base concentrated in a handful of recognizable brands. The core business is centered on therapies for pulmonary arterial hypertension (PAH) and, more recently, pulmonary hypertension associated with interstitial lung disease (PH-ILD). Key commercial products include Tyvaso and Tyvaso DPI, Remodulin, Orenitram, and Adcirca. United Therapeutics also markets Unituxin, an FDA-approved antibody therapy for high-risk neuroblastoma, a rare pediatric cancer. This product mix makes the company stand out: it combines orphan-disease exposure with high-value specialty pharmaceuticals, while remaining highly dependent on execution in commercialization, reimbursement access, and intellectual-property protection. From a historical perspective, United Therapeutics was founded in 1996 and has evolved from a niche therapeutics company into a broader biopharmaceutical group. The company emphasizes research, clinical development, and pipeline expansion, which are intended to extend the life cycle of existing franchises and create future growth drivers. Its geographic footprint remains predominantly U.S.-based, with a major operational presence in Silver Spring and an additional hub in Research Triangle Park, North Carolina. Competitively, United Therapeutics has established a strong position in PAH through brand recognition, clinical expertise, and long-standing relationships with specialist prescribers. Management highlights its capabilities in inhaled and prostacyclin-based therapies, where differentiation depends not only on efficacy but also on ease of administration and patient support. The portfolio is concentrated, but it supports meaningful cash flow visibility and a durable specialty-pharma profile. Recent highlights include the company’s report in July 2025 of record quarterly financial results, driven by double-digit growth in products such as Tyvaso DPI, nebulized Tyvaso, Orenitram, and Unituxin. Investors should nevertheless monitor pipeline milestones, potential competition across key franchises, and evolving regulatory dynamics. Overall, UTHR remains a high-quality healthcare/pharma name with a niche growth profile, listed on the NASDAQ in the United States and anchored by specialty respiratory and rare-disease franchises.